An Alzheimer’s blood test found a signal—the blind test had 23 people
A cell-based assay used machine learning to distinguish early Alzheimer’s disease from unaffected controls. The result is exploratory: external validation was modest, the blind test was small and the platform’s developers held a commercial interest.
The short version
- What happened
- The exploratory model used 191 archived plasma samples: 86 for training, 82 from two external cohorts for validation and 23 in a held-out blind test.
- Who it affects
- People seeking answers about memory symptoms need tests that work in the messy reality of clinical care. This study is too small and selected to support an individual diagnosis or treatment decision.
- What remains unproven
- Retrospective archived samples; 23-person blind set; blind-set reuse across 12 prior evaluations; selected high-confidence classes; cohort storage differences; no clinical threshold analysis; developer employment and equity interests.
Keep in mind
Retrospective archived samples; 23-person blind set; blind-set reuse across 12 prior evaluations; selected high-confidence classes; cohort storage differences; no clinical threshold analysis; developer employment and equity interests.
Source analysis · 1 linked source. Primary analysed source date: 17 October 2026.
Read the full report · 3 min The evidence, methods, implications and limitations
The assay asks cultured neurons to reveal a blood signal
Instead of directly measuring amyloid or tau, the iCAP method exposed standardised cultured neurons to participant plasma and read the cells’ gene-expression response. A random-forest classifier then used five genes selected from an independently derived 84-gene panel to separate early symptomatic Alzheimer’s disease from unaffected controls.
The primary model included 191 retrospective samples: 86 for training, 82 from two other cohorts for external validation and 23 held blind. The training cross-validation AUC was 0.79, external validation fell to 0.64, and the blind set produced 0.77 with a 95% confidence interval spanning 0.57 to 0.96.[1]
Why the uncertainty matters for families
An AUC measures ranking, not the number of people correctly diagnosed at a chosen threshold. The study did not establish sensitivity, specificity or predictive value for a real memory-clinic population, and it deliberately focused on participants with high-confidence classifications rather than ambiguous cases where a new test is most needed.
The blind set contained only eight early-stage cases and 15 controls. It had also been reused across 12 previous model evaluations, which the authors say can inflate family-wise error. Samples were archived for years, and the external cohorts used different stabilisation and storage conditions from the training and blind samples.[1]
The distinction that matters
What the experimental test actually measures
The platform turns a person’s plasma into a cellular response before machine learning classifies the pattern.
Expose
Add archived plasma to standardised neurons
Cells produce a gene-expression response
Classify
Use five genes in a random-forest model
Rank early-stage cases against controls
Validate
Test 82 external and 23 blind samples
Promising but imprecise discrimination
The next study must be prospective and independent
A genuinely complementary blood signal could help researchers stratify trials or investigate disease biology beyond amyloid. It should not yet guide a diagnosis, reassure a worried person or determine access to treatment.
Confidence would rise with a preregistered prospective cohort, a new untouched test set, representative memory-clinic patients, standardised sample handling and head-to-head comparison with established plasma biomarkers. Independent replication matters because several authors were PreCyte employees or shareholders and the company developed iCAP.[1]